EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus

G. Kirtschig*, M. Kinberger, A. Kreuter, R. Simpson, A. Guenthert, C. van Hees, K. Becker, M. J. Ramakers, M. Corazza, S. Mueller, S. von Seitzberg, M. J. Boffa, R. Stein, G. Barbagli, C. C. Chi, J. N. Dauendorffer, B. Fischer, M. Gaskins, E. Hiltunen-Back, A. HoefingerN. H. Koellmann, H. Kuehn, H. K. Larsen, M. Lazzeri, W. Mendling, A. F. Nikkels, M. Promm, K. K. Rall, S. Regauer, M. Sardy, N. Sepp, T. Thune, A. Tsiogka, S. Vassileva, L. Voswinkel, L. Woelber, R. N. Werner

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: Lichen sclerosus (LS) is an inflammatory skin disease affecting all ages. LS typically involves the anogenital site where it causes itching and soreness; it may lead to sexual and urinary dysfunction in females and males; however, it may be asymptomatic. First signs of LS are usually a whitening of the genital skin, sometimes preceded by redness and oedema; fissuring, scarring, shrinkage and fusion of structures may follow in its course. LS is associated with an increased risk of genital cancer. LS has a huge impact on the quality of life of affected patients, and it is important to raise more awareness of this not uncommon disease in order to diagnose and treat it early. Objectives: The guideline intends to provide guidance on the diagnostic of LS (part 1), highlight important aspects in the care of LS patients, generate recommendations and treatment algorithms (part 2) on topical, interventional and surgical therapy, based on the latest evidence, provide guidance in the management of LS patients during pregnancy, provide guidance for the follow-up of patients with LS and inform about new developments and potential research aspects. Materials and Methods: The guideline was developed in accordance with the EuroGuiDerm Methods Manual v1.3 https://www.edf.one/de/home/Guidelines/EDF-EuroGuiDerm.html. The wording of the recommendations was standardized (as suggested by the GRADE Working Group). The guideline development group is comprised of 34 experts from 16 countries, including 5 patient representatives. Results: Ultrapotent or potent topical corticosteroids in females and males, adults and children remain gold standard of care for genital LS; co-treatment with emollients is recommended. If standard treatment fails in males, a surgical intervention is recommended, complete circumcision may cure LS in males. UV light treatment is recommended for extragenital LS; however, there is limited scientific evidence. Topical calcineurin inhibitors are second line treatment. Laser treatment, using various wave lengths, is under investigation, and it can currently not be recommended for the treatment of LS. Treatment with biologics is only reported in single cases. Conclusions: LS has to be diagnosed and treated as early as possible in order to minimize sequelae like scarring and cancer development. Topical potent and ultrapotent corticosteroids are the gold standard of care; genital LS is often a lifelong disease and needs to be treated long-term.
Original languageEnglish
Number of pages36
JournalJournal of the European Academy of Dermatology and Venereology
DOIs
Publication statusE-pub ahead of print - Jun 2024

Bibliographical note

Publisher Copyright:
© 2024 European Academy of Dermatology and Venereology.

Fingerprint

Dive into the research topics of 'EuroGuiderm guideline on lichen sclerosus-Treatment of lichen sclerosus'. Together they form a unique fingerprint.

Cite this